Acceptable outcomes of donor-specific antibody (DSA)-positive living kidney transplantation (LKT) have recently been reported. However, LKT in crossmatch (XM)-positive patients remains at high-risk and requires an optimal desensitization protocol. We report our intermediate-term outcomes of XM-positive LKT vs. XM-negative LKT in patients who underwent LKT between January 2012 and June 2015 in our institution. The rate of acute antibody-mediated rejection (ABMR) within 90 days postoperation, graft function, and patient, and graft survival rates at 4 years were investigated. Patients were divided into three groups: XMÀDSAÀ (n = 229), XMÀDSA+ (n = 36), and XM + DSA+ (n = 15). The XM + DSA+ group patients underwent desensitization with high-dose intravenous immunoglobulin, plasmapheresis, and rituximab. The rates of ABMR within 90 days in the XMÀDSAÀ, XMÀDSA+, and XM + DSA+ groups were 1.3%, 9.4%, and 60.0%, respectively (P < 0.001). There were no significant differences in the graft function throughout the observational period, the 4-year patient or graft survival rates among three groups. This study showed that intermediate-term outcomes of XM-positive LKT were comparable to XM-negative LKT. However, our current desensitization protocol cannot avert ABMR within 90 days, and XM positivity is still a significant risk factor for ABMR. Further refinement of the current desensitization regimen is required.
Introduction
Living kidney transplantation (LKT) is the treatment for end-stage renal disease and offers a better quality of life and survival advantage in comparison with chronic hemodialysis [1] . Donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and significant immunologic barrier to graft and patient survival. In particular, highly-sensitized (e.g., complementdependent cytotoxicity crossmatch [CDCXM] or flow cytometric crossmatch [FCXM] positive) patients have increased the risk of ABMR and early graft loss in LKT.
Pretransplant desensitization therapy, such as plasmapheresis (PP), B lymphocyte-depleting agents, and intravenous immunoglobulin (IVIG), have been developed by various institutions for the purpose of preventing ABMR [2] [3] [4] [5] [6] [7] [8] [9] and improving graft survival. Two desensitization regimens are now widely accepted for their efficacy: low-dose IVIG/plasma exchange and high-dose IVIG with or without rituximab. The goal of desensitization is to lower the DSA level to below the threshold capable of developing ABMR, and to maintain a low level in the immediate post-transplant period. Different protocols have been used to achieve this goal and are determined by recipients' baseline crossmatch (XM) DSA level [10, 11] . These desensitization therapies have enabled highly-sensitized patients to receive kidney transplantation (KT) [12, 13] . Nevertheless, XM-positive LKT leads to inferior graft survival compared with XMnegative LKT [14, 15] . In addition, few studies have examined the intermediate-to long-term outcomes of XM-positive KT.
We hereby report our outcome data, emphasizing a risk-stratified desensitization protocol for DSA positive LKT.
Materials and methods

Study population
We performed a retrospective, observational study of 280 patients who underwent LKT from January 2012 to June 2015 in our institution. Data were extracted from the Japan Academic Consortium of Kidney Transplantation study (UMIN Clinical Trials Registry Number: UMIN000018327). The study protocol was approved by the research ethics committee (approval number: 3366-R), consistent with the Declaration of Helsinki. All patients have provided written informed consent. Prior to transplantation, we classified patients into three groups based on immunological risk stratification. This classification was then used to choose the specific transplant protocol for each group. In this study, we analyzed the rate of acute ABMR, graft function, patient, and graft survival at 4 years, and incidence of infectious events. Graft function was assessed by the estimated glomerular filtration rate calculated by the four-variable modification of renal disease equation.
Immunological risk stratification
Complement-dependent cytotoxicity crossmatch, FCXM, and Luminex single antigen beads assay (One Lambda Inc., Canoga, Park, CA, USA) for the detection of DSA were performed on all patients before transplantation. DSA strength was assessed by mean fluorescence intensity (MFI). Patients' MFI were checked before desensitization and at the time of KT. According to the results of CDCXM and FCXM predesensitization, all patients were stratified into three immunological risk groups as follows: "XM + DSA+" for positive FCXM and/or CDCXM and positive DSA; "XMÀDSA+" for negative CDCXM and FCXM and positive DSA; and "XMÀDSAÀ" for negative CDCXM and FCXM and negative DSA. Before and after KT, we determined the sensitivity status of all patients using complement-dependent cytotoxicity (CDC) and FCXM according to the manufacturer's instructions. Patients with more than 31% CDC positivity were considered a contraindication for living KTs. Patients with less than 30% CDC and/or positivity for FCXM were considered to be indicated for a desensitization protocol using high-dose IVIG treatment in this study. Briefly, FCXM was measured using an FACS Caliber (Becton Dickinson, San Jose, CA, USA). FCXM was routinely performed at the first visit, À1 day immediately before and after KT to check the status and confirm the negative conversion from positive to negative by FCXM, regardless of the DSA intensity by the Luminex single antigen beads assay. Examinations using pronase were conducted after rituximab (anti-CD20 antibody) administration to avoid the false-positive reaction of lymphocytes absorbed with rituximab. The Luminex single antigen beads assay was also conducted according to the manufacturer's instructions as previously described. We defined positive DSA as greater than 1000 MFI and positive FCXM as a shift greater than over 10 and/or ratio over 2.0 compared to the median MFI of a negative control.
Immunosuppression regimens and desensitization protocols
XM + DSA+ group: patients with XM + DSA+ received IVIG 4-6 times (total 2-4 g/kg), according to their DSA MFI level, followed by 2-4 sessions of double filtration plasmapheresis (DFPP) before transplantation. Five patients received IVIG 2 g/kg, one patient received 3 g/ kg, and nine patients received 4 g/kg. Rituximab was administered intravenously at a dose of 300 mg at 1 month, and an additional 200 mg the day before transplantation. Desensitization was deemed successful when there was a negative conversion of XM. Oral tacrolimus (TAC), mycophenolate mofetil (MMF), and methylprednisolone (MP) were initiated 1 month before transplantation. Basiliximab is administered at a dose of 20 mg/day at the time of the operation and on postoperative day 4.
XMÀDSA+ group: patients with XMÀDSA+ received 2 DFPP before transplantation. Rituximab was administered intravenously at a dose of 200 mg the day before transplantation. Oral TAC, MMF, and MP were initiated 7 days before transplantation. Basiliximab was administered on the operative day and postoperative day 4. Desensitization was deemed successful when there was a decrease in DSA MFI.
XMÀDSAÀ group: This group received neither pretransplant conditioning nor post-transplant therapy directed against DSA. TAC, MMF, MP, and basiliximab were administered in the same way as the XMÀDSA+ group.
Diagnosis of rejection
The diagnosis of ABMR was confirmed by the detection of DSA and pathological findings, which included any of the following microvascular injuries: peritubular capillaritis (ptc > 0), glomerulitis (g > 0), thrombosis, and transplant glomerulopathy (cg > 0). The types of rejection were classified using the Banff classifications (2009 and 2013). Protocol biopsies were performed at 1, 3, and 12 months post-transplantation and, if possible, annually. A biopsy was performed whenever rejection was suspected. All biopsy specimens were evaluated using light microscopy, and the specimens obtained were evaluated for C4d using immunofluorescence staining. Two or three core biopsy samples were obtained using a spring-loaded 16-gauge biopsy gun under ultrasound guidance. A diagnosis of rejection was made in a blinded manner by the same pathologist.
Infection prophylaxis
All transplanted patients received Pneumocystis jiroveci pneumonia and bacterial prophylaxis with trimethoprim-sulfamethoxazole (80 mg/400 mg daily on every other day) from 2 weeks after transplantation for the rest of their lives in our center. However, routine cytomegalovirus prophylaxis (IV ganciclovir or oral valganciclovir) was not initiated, even in donor-positive, recipient-negative cytomegalovirus serostatus patients.
Statistical analysis
Statistical analyses were performed with SAS, version 9.4 TS1M5 (SAS Institute, Cary, NC, USA). One-way analysis of variance was used to compare normally distributed continuous variables, and the Kruskal-Wallis H test was used to evaluate skewed or discrete ordinal variables. The chi-square test was used to compare nominal scale variables. Time-to-event analyses were performed using the Kaplan-Meier method and Cox proportional hazard model. The proportional hazard assumption was confirmed by the following equation: ln [Àln (survival function)]. This sample size of 280 had more than 90%, 63%, and 37% power to detect difference of time-to-event curves on ABMR, graft survival, and patient survival with a = 0.05. (two-tailed). A twotailed P-value <0.05 was considered statistically significant by the biostatistics datacenter (STATZ Institute, Tokyo, Japan).
Results
Baseline demographic and transplant characteristics of the cohort are summarized in Table 1 . The XMÀDSAÀ, XMÀDSA+, and XM + DSA+ groups consisted of 229 (82%), 36 (13%), and 15 (5%) patients, respectively. Unrelated donors were significantly different between the three groups. The ratio of patients with sensitizing events, previous transplant, transfusion, and pregnancy was significantly higher in the XM + DSA+ group than the XMÀDSA+ and XMÀDSAÀ groups. Both T-cell and B-cellFCXM in the XM + DSA+ group became negative at the time of transplantation. Table 2 shows characteristics in the XM + DSA+ group. Two patients were T-cell CDCXM positive, three patients were T-cell FCXM positive, and 11 patients were B-cell FCXM positive. In the XM + DSA+ group, DSA was detectable after desensitization in 10 patients, and MFIs ranged from 300 to 5897. DSA became undetectable in seven patients at the last follow-up time.
Change of estimated glomerular filtration rate (GFR) in each group is demonstrated in Fig. 1 in the XMÀDSAÀ, XMÀDSA+, and XM + DSA+ group, respectively, at 4 years post-transplant. The XM + DSA+ group had lower estimated GFR, but there was no significant difference in proteinuria incidence between the three groups at 4 years post-transplant (P = 0.81).
Figures 2(a and b) demonstrate the 4-year patient and graft survival rates for all patients. The 4-year patient survival rates were 98.3% (three deaths), 100% (zero deaths), and 93.3% (one death) in the XMÀDSAÀ, XMÀDSA+, and XM + DSA+ group, respectively, with no significant difference (P = 0.18).
Three patients in the XMÀDSAÀ group died due to cardiovascular disease, while one patient in the XM + DSA+ group died of suicide. All causes of death did not relate to graft rejection. The 4-year graft survival (non-censored for death) rates were 96.9%, 97.2%, and 86.7% in the XMÀDSAÀ, XMÀDSA+, and XM + DSA+ group, respectively, with no significant difference (P = 0.11).
Figure 2(c) shows the ABMR free-survival rate within 90 days post-transplantation. Biopsy-proven acute ABMR rates within 90 days postoperation was 1.3% (3/229) in the XMÀDSAÀ group, 19.4% (7/36) in the XMÀDSA+ group, and 60% (9/15) in the XM + DSA+ group ( Table 2) . The ABMR incidence rate in the XM + DSA+ group was higher than the XMÀDSA+ group (Hazard ratio; 3.81, 95% confidence interval; 1.41-10.30, P = 0.008). Similarly, without ABO-incompatible patients, the ABMR incidence rate in the XM + DSA+ group was significantly higher than that in the other two groups (XMÀDSAÀ vs. XMÀDSA+ vs. XM + DSA+: 1.3% vs. 17.4% vs. 55.6%, P < 0.001). Two patients in the XM + DSA+ group developed ABMR and required dialysis due to oliguria within the first week of transplantation. After IVIG therapy, graft function of both patients recovered. No patient required transient hemodialysis posttransplantation in both the XMÀDSA+ and XMÀDSAÀ groups. Four XM + DSA+ patients were diagnosed as having ABMR and received IVIG and/or PP without transient hemodialysis. All patients have stabilized serum creatinine at the last follow-up. Four, five, and two patients were diagnosed with ABMR by protocol biopsy in the XMÀDSAÀ, XMÀDSA+, and XM + DSA+ group, respectively. Interestingly, no patient developed de novo DSA during the study period. Table 3 demonstrates the infectious complications within 1 year post-transplantation in all groups. There was no significant difference in the incidence of each infectious complication (pneumonia, urinary tract infection, cytomegalovirus, BK virus, and adenovirus) between the three groups. Table 4 demonstrates the relationship between DSA and the incidence of ABMR in the XM + DSA+ group. We investigated the highest and total MFI pre-and postdesensitization. There was a significant difference between ABMR+ and ABMRÀ in both the highest and total MFI during predesensitization (11 186 [7379] Histological outcomes in the latest biopsy among the three groups are shown in Table 5 . Two hundred thirteen patients (93%), 35 patients (97%), and 14 patients (93%) were in the XMÀDSAÀ, XMÀDSA+, and XM + DSA+ groups. In the XM + DSA+ group, the Log-rank test P = 0.176 microvascular inflammation score and incidences of transplant glomerulopathy and interstitial fibrosis and tubular atrophy tended to be higher than those in the other two groups. 13 [6] ABMR, acute antibody mediated rejection; DS, desensitization; DSA, donor specific antibody; IQR, interquartile range; MFI, mean fluorescence intensity; XM, crossmatch. Discussion XM-positive LKT recipients have higher risk for ABMR and early graft loss. Our study clearly showed the intermediate-term outcomes of XM-positive LKT recipients desensitized by a risk-stratified protocol. Various desensitization protocols have been introduced by many studies [14] [15] [16] [17] . Each protocol has produced varying successful outcomes of XM-positive kidney transplantation; however, an optimal desensitization protocol has not yet to be established. The major desensitization protocol is PP and low-dose IVIG without rituximab. Haririan et al. [17] reported intermediate-to long-term outcome of protocol consisted of PP and low-dose IVIG. Our protocol consisted of PP, high-dose IVIG, and rituximab, and is initiated 1 month prior to transplantation. The outcome of a desensitization protocol like this is rarely reported; therefore, it was important to determine the effectiveness of our protocol. Our findings demonstrated that the intermediate-outcomes of XM-positive LKT were comparable to XM-negative LKT. In terms of patient and graft survival rates and graft function, there were no significant differences between the higher and lower immunological risk groups. However, the occurrence of ABMR was significantly higher in the XM-positive group, in spite of our strict desensitization protocol. Bentall et al. [16] demonstrated the 5-year outcome in XM-positive LKT by utilizing three desensitization protocols: (i) PP with low-dose IVIG plus splenectomy at the time of transplant; (ii) PP with IVIG (2 g/kg) without splenectomy; and (iii) high-dose IVIG alone. They showed that there was significantly worse 5-year death-censored graft survival rate and incidence of ABMR in XM-positive patients (70.7% vs. 88.0%, and 37.2% vs. 2.5%, in positive and negative XM patients, respectively). Haririan et al. [17] showed similar intermediate-to long-term outcomes in XM-positive LKT recipients who received PP and low-dose IVIG. Previous studies have demonstrated inferior outcomes in graft survival and incidence of ABMR. In our study, deathcensored graft survival rates were 100% and 93.3% at 1-year and 4-year post-transplant, respectively. In spite of the small sample size of XM-positive patients, the intermediate outcome in graft survival was comparable with the nonimmunological group.
The XM + DSA+ group converted to negative XM and showed decreasing levels of DSA at transplantation following desensitization. Surprisingly, the incidence of ABMR remained considerably high in the XM + DSA+ group. Our study found that the incidence of ABMR within 3 months is 60%; importantly, all patients developed ABMR within 1 month after KT [13 days (10-16) ], in spite of negative XM at transplantation. Treatment for ABMR includes steroid pulse, high-dose IVIG, and/or plasma exchange, rituximab, or bortezomib [18, 19] . All patients who developed ABMR showed favorable responses to ABMR treatment. Graft survival was excellent and showed no difference with the XMÀDSAÀ group. Our study also suggested that DSA MFI predesensitization have been associated with the incidence of ABMR, while DSA MFI postdesensitization have not been associated with ABMR. We postulate that the reason for high incidence rate of acute ABMR may be secondary to rebound DSA MFI. In our protocol, rituximab was administered at a dose of 300 mg at 1 month, and an additional 200 mg the day before transplantation. This method of administration of rituximab may not be sufficient to suppress rebound DSA MFI. To increase the transplant rates in sensitized patients, new protocols for HLA sensitization have emerged.
The effect of blocking terminal complement activation is expected for the purpose of preventing ABMR. Eculizumab is a novel desensitization agent for highly-sensitized patients and has terminal complement inhibition with the humanized anti-C5 antibody. Stegall et al. [20] reported the outcome of highly-sensitized patients with plasma exchange, IVIG, and eculizumab. The incidence of ABMR was only 7.7% in the eculizumab group compared to 41.2% in the control group. On the other hand, bortezomib, which inhibits 26S proteasome selectively, is widely used for plasma cell targeted therapy as a novel agent. Successful desensitization with bortezomib for high ABO titers or highly-sensitized transplantation has been reported in multiple centers [21] [22] [23] . Woodle et al.
[24] reported consistent reduction of DSA levels in bortezomib-based desensitization without IVIG.
Previous studies suggested that highly-sensitized patients who received rituximab tended to be at an increased risk of viral and bacterial infections [25, 26] . On the other hand, Kahwaji et al.
[27] reported comparable incidence of infection in the desensitization group of ABO-incompatible transplant patients given rituximab and high-dose IVIG in comparison with the nondesensitization group. With regards to the risk of infection, we did not find significant differences in the incidence of infection between the three groups in the present study. IVIG is also considered to be the treatment of infection besides its effect of desensitization. We speculate that high-dose IVIG may have led to acceptable infection outcome post-transplantation among highly-sensitized patients.
The current study has several limitations. First, the small sample size of the high-risk group limits the power of the study, in terms of determining the significance of outcomes between the three groups, as well as the DSA status in the high-risk group. Secondary, crossmatch assays and definitions vary between different centers; therefore, our results should be applied carefully.
In conclusion, our desensitization protocol, which consisted of high-dose IVIG, PP, and rituximab, is effective for highly-sensitized LKT recipients, and provides acceptable graft survival outcome without adverse events. Nevertheless, prevention of postoperative ABMR is still difficult in spite of strict desensitization protocol. Further refinement of our current desensitization regimen is required. In addition, the development of novel agents and more effective protocols is warranted to improve the outcomes of LKT among highly-sensitized recipients.
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